Delivering the Promise of Healthier LivesTM

AUGUST 2019

OTCQB: CURROTCQB: CURR

®

© 2

01

9 C

UR

E P

harm

aceutical

Forward LookingStatements

To the extent any statements made in this presentation contains forward looking statements and information that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and assumptions made by the company’s management. When used in this presentation the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions as they relate to the company or the company’s management identify forward looking statements.

Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Although the company believes that the expectations reflected in the forward looking statements are reasonable, the company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our mission is to improve lives by redefining how medications are delivered and experienced.

© 2

01

9 C

UR

E P

harm

aceutical

CUREPharmaceutical

We are an oral delivery company that develops and manufactures innovative formulations and dosage forms:

CUREform™

We improve absorption and

release of medicines and

supplements into the body

for easier, safer and more

effective administration.

We work with companies

with shared values to market

and distribute

pharmaceutical products and

dietary supplements.

What we do How we do it

© 2019 CURE Pharmaceutical

The Problem: Oral delivery is flawed

POOR BIOAVAILABILITYFor many molecules given orally, only a fraction of the

administered dose will make it to the blood due to poor

solubility or degradation in the GI tract and liver.

Almost 70% of Americans are on prescription medication.1

Oral drug delivery is the most preferred route of drug administration.

NON-ADHERENCEWhen drugs don’t work well enough and cause side effects, patients

stop taking them.

● 30-50% of Americans do not take medications as prescribed.2

● 40% of patients have trouble swallowing pills.3

SIDE EFFECTSWhen only a fraction of the administered dose reaches the

blood, more drug needs to be given which can cause GI irritation

and liver toxicities.

© 2

01

9 C

UR

E P

harm

aceutical

CUREfilm®

dissolving film technologyCUREpods™

chewable pod technology

The Solution:

Our proprietary oral formulation and delivery platformCUREform™

© 2

01

9 C

UR

E P

harm

aceutical

CUREform™

The RightDosage Form

The Right Formulation

Impacts the route of administration and metabolism

Improves solubility and

absorptionCUREfilm®

CUREpods™

CUREform™

© 2

01

9 C

UR

E P

harm

aceutical

CUREfilm®The Right Dosage Form

Unique Attributes● Sublingual and buccal delivery options for direct

absorption into the bloodstream, avoiding first-pass

metabolism

● No need for water, swallowing or chewing

● Uniform drug distribution allows for precision dosing

Dose Loading● Multiple actives up to 200mg

● Stable at room temperature

Applications● Suitable for both pharmaceuticals and nutraceuticals

© 2

01

9 C

UR

E P

harm

aceutical

CUREpods™The Right Dosage Form

Unique Attributes● Simultaneously load fat soluble and water soluble

molecules

● Controlled time, temperature and pH triggered

release of actives

● Overcomes problems with poorly soluble and

poorly absorbed nutrients

● Multiple shapes, sizes, flavors and colors

Dose Loading● High doses of actives (grams)

Applications● Ideal for nutraceuticals

© 2

01

9 C

UR

E P

harm

aceutical

CUREform™The Right Formulation

PROTECTION FROM DEGRADATION during manufacturing,

throughout shelf life

and from stomach acids

INCREASED BIOAVAILABILITY

through greater water

solubility, enhanced

permeability and

retention in

target tissue

BETTER PALATABILITY

through improved

taste masking

SPECIFIC RELEASE PROFILES

(e.g. immediate or

controlled release)

© 2

01

9 C

UR

E P

harm

aceutical

CUREformTM

Consumer Benefits

FAST SYMPTOM RELIEFRapid and/or sustained

delivery of active ingredients

NO PILLS TO SWALLOWIdeal for consumers that

cannot swallow pills PORTABLEDiscrete, lightweight and easy to transport

FEWER SIDE EFFECTSPotential to reduce the dose and avoid the GI tract

EASY TO TAKEPalatable with a pleasant mouth-feel and no water needed

© 2019 CURE Pharmaceutical

Strategic Approach

NUTRACEUTICALSTarget the growing wellness market

No FDA approval required

Faster and cheaper to launch than pharmaceutical medicines

CUREfilm® + CUREpods™

PHARMACEUTICALSNovel CUREfilm® drugs can be

approved via accelerated regulatory

paths such as 505(b)(2) and ANDAs with market exclusivity

CANNABINOIDSCUREfilm® + CUREpods™ cannabinoid products can be launched as nutraceuticals and pharmaceuticals

DEA Schedule 1 manufacturing license to formulate and manufacture cannabinoid drugs in-house

CUREform™ encapsulation to stabilize and improve the bioavailability of cannabinoids and terpenes

© 2

01

9 C

UR

E P

harm

aceutical

● cGMP 25,000 sq ft production plant in Oxnard, CA

● FDA-registered and audited facility ● Clean room environment● Pharmaceuticals, dietary supplements and

controlled substances (DEA schedule 1 manufacturing license)

● Expansion capability● Custom drug delivery systems developed in

a design control process

Our Capabilities

PROCESSDEVELOPMENT AND SCALE UP

cGMP MANUFACTURING FACILITY

PRODUCT DEVELOPMENT AND CHARACTERIZATION

INTELLECTUALPROPERTY

13issued U.S. patents

11patents pending

© 2

01

9 C

UR

E P

harm

aceutical

Revenue Streams

CONTRACT DEVELOPMENT AND MANUFACTURING

• Development fees• Manufacturing fees

IP LICENSING AND TECH TRANSFER

• License fees • Tech transfer fees

• Milestone payments• Royalties

IN HOUSE PRODUCT & CLINICAL DEVELOPMENT

• Upfront fees• Milestone payments

• Royalties• Manufacturing fees

© 2

01

9 C

UR

E P

harm

aceutical

Formulation Development/

Preclinical

Manufacturing Scale Up

Launch

CUREfilm® BLUE (Sildenafil Pre-IND)

Nutraceutical Pharmaceutical

CUREfilm®/CUREpod™ Hemp

ClinicalDevelopment

CUREfilm® Sleep (two different sleep & recovery products)

ProductPipeline

CUREfilm® Canna (THC & CBD)

CUREfilm® D (weekly vitamin D3)

CUREfilm® β-Caryophyllene

© 2

01

9 C

UR

E P

harm

aceutical

Market Opportunity

CUREfilm® Sleep

CUREfilm® Blue

CUREfilm® D

CUREfilm® β-Caryophyllene

CUREfilm®/CUREpod™ Hemp

CUREfilm® Canna

Global sales of melatonin supplements by 2024.4

Global CAGR by 2023.$2.1B 19.9% CAGR

Global sales of erectile dysfunction drugs by 2024.5

Global CAGR by 2018-2024.$7.1B 5.7% CAGR

Global sales of Vitamin D supplements by 2025.6

Global CAGR 2019-2025$1.7B 7% CAGR

Global sales of curcumin supplements by 2024.7

Global CAGR 2018-2024.$1.3B 12.3% CAGR

Global sales of cannabidiol (CBD) by 2022.8

Global CAGR 2017-2022.$1.9B 31% CAGR

Global sales medical cannabis by 2025.9

Global CAGR 2019-2025.$20.2B 24.4% CAGR

© 2

01

9 C

UR

E P

harm

aceutical

● Formerly President and CEO of InnoZen Inc., CEO of Gel Tech LLC, CEO of Bio Delivery Technologies Inc.

● Lead the development of several drug delivery technologies and commercial brand extensions including Chloraseptic™, Suppress™, as well as Pediastrip™,

● B.S. degree in Biological Life Sciences; Masters Certificate in Applied Project Management , Master’s in Public Health, Masters in Wellness, Post Graduate Qualification at the University of Cambridge.

● Formerly Head of Innovation at Children’s Hospital Los Angeles, licensing officer at The Scripps Research Institute and held research, clinical and business development positions held at GlaxoSmithkline Biologicals.

● Founder and director of one of seven national FDA-funded pediatric medical device accelerators.

● Masters in Biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France.

Jessica RoussetCOO

● Formerly CFO, vice president and general manager positions with several venture and private equity backed companies including Inogen, Medical Analysis Systems (acquired by Thermo Fisher Scientific), CDTi Advanced Materials, and Abrisa Technologies.

● Earlier experience includes management roles with Pepsi and in public accounting.

● CPA (inactive) with a B.S., Business Administration from California Polytechnic State University, San Luis Obispo.

MikeRedardCFO

Our Team: Officers

Robert DavidsonCEO

© 2

01

9 C

UR

E P

harm

aceutical

● Over 35 years of experience leading technical teams.

● Leadership roles in process development at Amgen Thousand Oaks and Ireland

● Management positions at CancerVax, Certified Facilities, IDEC Pharmaceuticals, Xoma and Celtrix Pharmaceuticals.

● Trained as microbiologist and chemist at Brigham Young University.

● Formerly Project Leader with the Boston Consulting Group focused on corporate and network strategy, operations, marketing and post-merger integration initiatives.

● PhD in Immunology from the University of Pennsylvania; BSc. in Bio-Medical sciences from Tel-Aviv University in Israel.

Vered GigiVP, Strategy & Business Development

● Formerly Chief Accounting Officer and Controller at InnoZen, Inc.

● Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. CPA and B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

Mark UdellCAO

Our Team: Senior Leadership

Steven RuhlVP, Manufacturing

© 2

01

9 C

UR

E P

harm

aceutical

Board of DirectorsWilliam Yuan (Chairman of the Board)

● Chairman and CEO of Fortress Hill Holdings, an Asian-based investment banking firm.

● 23 years in global finance experience.● Key strategist and advisor to international institutions. U.S.

companies include Amgen Corp., Biogen, GE Capital, Warner Brothers Studios, and Fox News.

● Guided leading Asian institutions like Sina.com, Shanghai Petrochemicals, Jinlia Pharmaceutical and Tsingtao Beer Corp.Led Merrill Lynch Asset Management Asia,

● Managed one of the largest pension / retirement funds in the world, with a $488 billion portfolio.

● Member of the International Who’s Who of Finance, Technology, Media and Telecom.

● B.S. in Economics from Cornell University● Attended as a Mason Fellow at Harvard University’s John F.

Kennedy School.

Lauren Chung, Ph.D.

● 20 years of healthcare investment management and advisory experience.● Founded MINLEIGH LLC. identifying, evaluating and partnering with

companies for investments and various strategic, operational, and commercial planning, as well as providing growth capital.

● Managing Director in Healthcare Research at WestPark Capital.● Former Senior Healthcare Equity Analyst at Maxim Group. ● Co Founder of Tokum Capital , a global healthcare fund.● Managed healthcare investment portfolios at RBR Capital, Kingdon

Capital, and Pequot Capital. ● Recognized research scientist conducting cutting edge research in the field

of Alzheimer’s disease and Angelman Syndrome at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital.

● Serves as a board member in various private healthcare companies. ● PhD in Neuropathology from Columbia University-College of Physicians &

Surgeons, and a BA with honors in Biochemistry and Economics from Wellesley College.

© 2

01

9 C

UR

E P

harm

aceutical

Rob Davidson

● CEO of CURE Pharmaceutical ● Former President and CEO of InnoZen Inc., CEO of Gel Tech LLC,

CEO of Biodelivery Technologies Inc., and Director of HealthSport Inc.

● ODF expert responsible for the development of several drug delivery technologies and commercial brand extensions.

● Has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film.

● B.S., Biological Life Sciences, University of the State of New York, Excelsior College.

● Master’s Certificate, Applied Project Management , Villanova University

● Master’s, Public Health from American Military University, Virginia

● Masters in Health and Wellness from Liberty University, Virginia ● Certified Performance Enhancement Specialist and Fitness

Nutrition Specialist, National Academy of Sports Medicine● Post-Graduate Qualification, University of Cambridge.

Anya Goldin

● 28 years of experience in law, private equity, venture capital, healthcare and telecommunications industries.

● Former international business consultant ● A practicing attorney at Nolan Heimann law firm ● Co-founded Provenance Laboratories, a technology start-up. ● 17 years in leadership as a managing partner at Latham & Watkins ● Served as the General Counsel, Vice President and Chair of the Risk

Management Committee of a $20-billion London Stock Exchange-listed conglomerate and served on the boards of eight public and private companies in Europe, Russia, India and the UK

● Vice Chair of the Board of Directors for a global private equity fund ● On the Advisory Board of a California private equity fund, Lumia Capital.● On the Board of Trustees of Westmark School, and on the Board of the LA

Chapter of Berkeley Law Alumni ● A member of the State Bar of California● BA in Mass Communications from University of California Berkeley● JD from University of California Berkeley School of Law

Board of Directors(continued)

© 2

01

9 C

UR

E P

harm

aceutical

Board of Directors(continued)

Joshua Held

● Currently the President of Form Factory Inc. a wholly owned subsidiary of Acreage Holdings (ARCG.CN) the largest multi-State cannabis operator licensed in 20 States.

● Founder and CEO of Chemistry Holdings, Inc. a formulation technology company that creates innovative, sustainable delivery systems for a variety of industries. Chemistry Holdings was recently acquired by Cure Pharmaceutical.

● CEO and founder of Made by Science (rebranded as Form Factory Inc) . a private company acquired by Acreage Holdings for $160 Million in December of 2018.

● Former Vice President of Investments for JP Morgan, managing more than $100 million in investment dollars for high-net-worth individuals and families.

● Bachelor of Arts from the California State University, Long Beach.

Ruben Jose King-Shaw Jr.

● C-suite positions with leading private companies including Steward Health Care System, LLC, Neighborhood Health Partnership, Inc. and JMH Health Plan.

● Former Board member, Cotiviti Holdings, Inc. and current Board member, Intelligent Retinal Imaging Systems of Pensacola, FL.

● Former Lead Director of the Board at Athenahealth; Independent Living Systems, of Miami, FL; and WellCare Health Plans, Inc. of Tampa, FL.

● Served on the Obama Administration's Medicare Program Advisory and Oversight Committee,

● COO and deputy administrator of the Centers for Medicare and Medicaid Services, George W. Bush administration.

● Advisor, healthcare policy to the Trump Administration.● Senior advisor to the Secretary of the U.S. Treasury, health care tax

policies. ● B.S., Industrial and Labor Relations, Cornell University, Master of

Health Service Administration and a Master of International Business, Florida International University. Advanced studies in Corporate Governance at the Harvard Business School.

© 2

01

9 C

UR

E P

harm

aceutical

Board of Directors (continued)

Gene Salkind, MD

● Board certified in neurological surgery by the American Board of Neurological Surgery and completed various residencies, fellowships and postgraduate training at Abington Memorial hospital, The Graduate Hospital, Veteran’s Administration Hospital, Pennsylvania Hospital, Children’s Hospital of Philadelphia, and the Hospital of the University of Pennsylvania.

● MD from Temple University School of Medicine and his Bachelor of Arts from the University of Pennsylvania.

● Numerous faculty, hospital and administrative appointments at virtually every major hospital in the northeastern Philadelphia and surrounding areas.

● Prolific pharmaceutical investor including Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250/share, and Centocor, acquired by Johnson & Johnson for $4.9 billion in stock.

● Sits on the board of DermTech, a private company based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics.

© 2

01

9 C

UR

E P

harm

aceutical

Advisors

Michael Willner, Esq.

● Founder of Willner Properties Services, Inc., a PA based real estate development, leasing and management company specializing in both commercial and residential properties.

● Founder of Willner Capital, Inc., a FL based investment concern that has played an activist role with several publicly traded companies.

● Investor in biotech, technology and security companies, with recent focus in cannabis related pharmaceutical companies

● Served on the Board of Directors of publicly traded Meridian Bank, served as Vice Chairman of the Board of Directors of Intervoice, Inc.

● Held positions at Milbank, Tweed, Hadley & McCloy and Arthur Andersen & Company

● Juris Doctor degree from Emory University Law School and CPA

Michael Neely, MD

● Director of the University of Southern California Laboratory of Applied Pharmacokinetics, which has been at the forefront of nonparametric population pharmacokinetic modeling techniques and dose optimization for individual patients for over 35 years.

● Associate Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at Children’s Hospital Los Angeles.

● Research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients.

● Member of the United States Food and Drug Administration Anti- infective Drug Advisory Committee and board certified in pediatrics, pediatric infectious diseases and a Fellow of the American College of Clinical Pharmacology.

© 2

01

9 C

UR

E P

harm

aceutical

Advisors (continued)

Teresa Virgallito

● Expert in physical and mechanical encapsulation, ingredient engineering, food law regulations and food safety, microbiology and chemical instrumentation.

● Previously EVP of Chemistry Holdings, Inc. ● She has developed drug delivery and formulation solutions

for Procter & Gamble, Kraft, Unilever, Cargill, the U.S. Army, and the U.S. Navy.

● Through her research and commercialization endeavors, she has gained a wealth of knowledge and expertise in regard to the following encapsulation methods: Co-acervation, In-situ Polymerization, Interfacial Polymerization, Fluid Bed Technology, Spray Chilling, Hot Melt Systems, Prilling, Pan Coating, Phase Separation, and Spray Drying.

● Member of the Controlled Release Society active on several CRS committees.

© 2

01

9 C

UR

E P

harm

aceutical

CompanyDisclaimer

This Investor Presentation is supplied for informational purposes only and does

not constitute (1) an offer to sell, or the solicitation of an offer to buy, any securities of CURE Pharmaceutical, or (2) a promise or representation that any

such offer will be made to the recipient or any other party.

The offering is being made only to qualified investors. The offering shall be made

pursuant to documents reasonably acceptable to the Company and the Investors, which agreements shall contain, among other things, (i) short form, basic representations and warranties by the Company, and (ii) covenants of the Company reflecting the provisions set forth herein and appropriate conditions of closing.

Documents to be drafted by counsel to the company. Read those documents

before making an investment decision. The securities are being offered in reliance upon exemptions from registration under the Securities Act of 1993 and only in the states in which the offering of securities is registered or is exempt from registration and by broker-dealers authorized to do so.

© 2

01

9 C

UR

E P

harm

aceutical

Credits Title page photograph: copyright © Paul Bradbury, iStock

References:

1. Zhong, Wenjun et al. Age and Sex Patterns of Drug Prescribing in a Defined American Population (2013) Mayo Clinic Proceedings, Volume 88, Issue 7, 697-707 Retrieved from: https://www.mayoclinicproceedings.org

2. Marcum, Z. et al, Medication Nonadherence: A Diagnosable and Treatable Medical Condition (2013 May 22) JAMA; 309(20): 2105–2106. doi: 10.1001/jama.2013.4638 Retrieved from: https://www.ncbi.nlm.nih.gov

3. Fields, J. et al. (2015). Pill Properties that Cause Dysphagia and Treatment Failure. Current Therapeutic Research, Clinical and Experimental, 77, 79–82. doi:10.1016/j.curtheres.2015.08.002. Retrieved from: https://www.ncbi.nlm.nih.gov

4. Industry Research, 2018-2023 Global Melatonin Consumption Market Report (2018, Aug 2) Retrieved from: https://www.industryresearch.co

5. Zion Market Research, Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024 (2018, Oct) Retrieved from: https://www.globenewswire.com

6. MarketsandMarkets Inc., Vitamin D Market by Analog (Vitamin D2, Vitamin D3), Form (Dry, Liquid), Application (Functional Food & Beverage, Pharma, Feed, and Personal Care), End User (Children, Adult, and Pregnant Women), Iu Strength and Region - Global Forecast to 2025, (2019, May) Retrieved from: https://www.marketsandmarkets.com

7. Grandview Research, Curcumin Market Size, Share & Trends Analysis Report By Application (Pharmaceutical, Food, Cosmetics), By Region (Asia Pacific, North America, CSA, Europe, MEA), And Segment Forecasts 2018 - 2025 (2018, Sep) Retrieved from: https://www.grandviewresearch.com

8. Technavio Research, Global CBD Oil Market Analysis - Size, Trends and Forecast 2018-2022), (2018, July) Retrieved from: https://www.businesswire.com

9. Market Study Report, Global Medical Cannabis Market Insights, Forecast to 2025, (2019, June) Retrieved from: https://www.marketstudyreport.com